GlobeNewswire Inc | Jul 21, 2021 04:35PM EDT

July 21, 2021

Oral Presentation to Highlight Data from the Ongoing Phase 2 Study of AL001 in FTD-GRNCompany to Host Analyst and Investor Conference Call on July 29 at 1:00 p.m. ET

SOUTH SAN FRANCISCO, Calif., July 21, 2021 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced presentations at the upcoming 2021 Alzheimers Association International Conference being held July 26-30, 2021 virtually and in Denver, Colorado.

Among the data being presented at the conference will be six- and twelve-month data from the open-label Phase 2 INFRONT-2 study evaluating AL001 in individuals with frontotemporal dementia due to a progranulin gene mutation (FTD-GRN). Alector plans to host a conference call to review the AL001 Phase 2 results on July 29 at 1:00 p.m. ET.

Alector will also present two posters related to its AL002 Alzheimers disease (AD) program. The first poster will include the results of the AL002 Phase 1 study in healthy volunteers and the second poster will highlight the study design of the ongoing INVOKE-2 trial in people with early AD.

Oral Presentation for AL001 Phase 2 Data

Presentation Title Six Months Interim Analysis of the Phase 2 Study of AL001 in Frontotemporal Dementia Patients Carrying a Granulin Mutation (#54593)Session Name Human: A potpourri of human clinical trials Presenter Robert Paul, M.D., Ph.D., Chief Medical Officer, Alector Session Date and Time Thursday, July 29, 2021 at 10 a.m. ET

Poster Presentations for AL002Poster presentations will be available for on-demand viewing beginning on Monday, July 26.

Poster Title INVOKE-2 A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of AL002 in Participants with Early Alzheimers Disease (#54615) Presenting Author Robert Paul, M.D., Ph.D., Chief Medical Officer, Alector

Poster Title A Phase 1 Study of AL002 in Healthy Volunteers (#54669)Presenting Author Mike Ward, Ph.D., Senior Director, Clinical Science, Alector

Alector AL001 Conference Call InformationAlector management will host a conference call at 1:00 p.m. ET. Analysts and investors are invited to participate in the conference call by dialing (888) 705-0365 from theU.S.andCanadaor (415) 817-9241 internationally and using the conference ID 5267479. The live webcast can be accessed on the investor page of Alectors website atinvestors.alector.com. A replay of the webcast will be available on Alectors website approximately two hours after the completion of the event and will be archived for up to 30 days.

AboutAlectorAlectoris a clinical stage biotechnology company pioneering immuno-neurology, a novel therapeutic approach for the treatment of neurodegenerative diseases. The Companyis developing a broad portfolio of innate immune system programs, designed to functionally repair genetic mutations that cause dysfunction of the brains immune system and enable the rejuvenated immune cells to counteract emerging brain pathologies.Immuno-neurology targets immune dysfunction as a root cause of multiple pathologies that are drivers of degenerative brain disorders.The Companys immuno-neurology product candidates are supported by biomarkers and target genetically defined patient populations in frontotemporal dementia and Alzheimers disease. This scientific approach is also the basis for the Companys immuno-oncology programs.Alectoris headquartered inSouthSan Francisco,California. For additional information, please visitwww.alector.com.

Alector Contacts:

Michelle CorralVP, Communications and Investor Relations650-808-7016michelle.corral@alector.com

1ABDan Budwick973-271-6085dan@1abmedia.com

Investors:Alector, Inc.ir@alector.com